文献类型：期刊文献

英文题名：Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma

作者：Dong, Lu[1];Wang, Pengbin[2];Pan, Yan[3];Sun, Naiying[1];Yin, Gang[1]

第一作者：董莉

通信作者：Yin, G[1]

机构：[1]Gansu Univ Chinese Med, Lanzhou Petrochem Gen Hosp, Gastroenterol Dept, Affiliated Hosp 4, 733 Fuli West Rd, Lanzhou 730060, Gansu, Peoples R China;[2]Second Peoples Hosp Lanzhou City, Gastroenterol Dept, 388 Jingyuan Rd, Lanzhou 730060, Gansu, Peoples R China;[3]Gansu Univ Tradit Chinese Med, Lanzhou Petrochem Gen Hosp, Radiol Dept, Affiliated Hosp 4, 733 Fuli West Rd, Lanzhou 730060, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Lanzhou Petrochem Gen Hosp, Gastroenterol Dept, Affiliated Hosp 4, 733 Fuli West Rd, Lanzhou 730060, Gansu, Peoples R China.|[10735]甘肃中医药大学;

年份：2024

卷号：16

期号：6

起止页码：2554

外文期刊名：AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001259851600035)】；

语种：英文

外文关键词：Programmed death-1; regorafenib; advanced hepatocellular carcinoma; prognosis

摘要：Objective: To investigate the therapeutic efficacy and safety of programmed death-1 (PD-1) inhibitors combined with regorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods: A retrospective analysis was performed on 82 patients diagnosed with advanced HCC at Lanzhou Petrochemical General Hospital and the Second People's Hospital of Lanzhou City from October 2021 to October 2022. Patients were divided into two groups: the observation group (42 patients) received combined therapy with regorafenib and a PD-1 inhibitor, while the control group (40 patients) received only regorafenib monotherapy. Treatment efficacy, changes in serum tumor markers pre- and post-treatment, incidence of adverse reactions, progression-free survival (PFS), 1-year survival rate, and independent prognostic factors were evaluated for both groups. Results: The treatment efficacy in the observation group was significantly better than that in the control group (P<0.05). Post-treatment levels of VEGF, sIL-2R, and CEA were significantly lower in the observation group compared to the control group (all P<0.05). The incidence of adverse reactions was similar between the two groups (P>0.05). However, the observation group demonstrated a significantly higher median PFS and 1-year survival rate than the control group (both P<0.05). Vascular invasion, degree of differentiation, and treatment regimen were identified as independent prognostic factors affecting outcomes (all P<0.05). Conclusion: For patients with advanced HCC, integrating PD-1 inhibitors with regorafenib treatment not only enhances clinical efficacy but also maintains safety. This combination therapy significantly improves progression-free survival and 1-year survival rates, supporting its further clinical application.